An Evaluation of Factors Contributing to Primary Nonresponse to Biological Therapy in Patients with Spondyloarthropathy: A Retrospective Cohort Study
Archives of Rheumatology, vol.41, no.3, pp.201-211, 2026 (SCI-Expanded, Scopus, TRDizin)
- Publication Type: Article / Article
- Volume: 41 Issue: 3
- Publication Date: 2026
- Doi Number: 10.5152/archrheumatol.2026.25237
- Journal Name: Archives of Rheumatology
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, TR DİZİN (ULAKBİM), Academic Search Ultimate (EBSCO), Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest)
- Page Numbers: pp.201-211
- Keywords: biological therapy, primary nonresponse, Spondylarthropathies, treatment failure
- Erciyes University Affiliated: Yes
Abstract
Background/Aims: Primary nonresponse to biological therapy in patients with spondyloarthropathy (SpA) is a considerable challenge. This study sought to identify the factors associated with primary nonresponse to biological therapy in a cohort of patients diagnosed with SpA. Materials and Methods: A retrospective analysis was performed on 261 patients with SpA who underwent at least 1 biological therapy. The incidence of primary nonresponse to any biological treatment was evaluated, and various clinical and demographic factors were analyzed for their potential associations with treatment outcomes. Results: The study found that the frequency of primary nonresponse to any biological disease–modifying antirheumatic drugs (bDMARDs) was 15.3% in the study population. In the logistic regression analysis of baseline parameters, presentation with arthritis at diagnosis was identified as a significant predictor of primary nonresponse (odds ratio: 2.113, 95% CI: 1.069-4.175, P = .031). Beyond this baseline predictor, primary non-responders significantly differed from responders by having higher frequencies of concomitant fibromyalgia (FMS) treatment (P = .047) and higher terminal C-reactive protein (CRP) levels (P = .030), as well as variations in acute-phase reactants, presence of psoriasis or enthesitis at diagnosis, and treatmentrelated factors such as bDMARDs duration. Conclusion: This study identifies baseline arthritis as a significant predictor of primary nonresponse to bDMARDs in SpA patients. Additionally, the presence of FMS and elevated CRP levels during follow-up are key clinical characteristics associated with the non-responder phenotype. These findings highlight the need for more objective assessment tools to distinguish true biological treatment failure from comorbid pain syndromes and the influence of disease phenotypes.